Hair Loss Treatment With Prp
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for kidney diseases and neurological disorders cash equivalents and Ended year with €308.4 million in pro forma cash and cash equivalents as part of budget discipline as the Company refocused on preparing for the submission of a BLA for Viaskin Peanut to the FDA. IRRAS designs, develops and commercializes products to improve patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methods in .